Kevin McCulloch - 12 Mar 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: President and Chief Operating Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 12 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 16 Mar 2026, 18:11:35 UTC
Previous filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
McCulloch Kevin	President and Chief Operating Officer	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	16 Mar 2026	0002031695

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Options Exercise		+48,894	+2.8%	$4.09^*	1,777,721	12 Mar 2026	Direct
transaction	XERS	Common Stock	Options Exercise		+4	+0%	$3.94^*	1,777,725	12 Mar 2026	Direct
holding	XERS	Common Stock						25,000	12 Mar 2026	By Spouse	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XERS	Stock Option (Right to Buy)	Options Exercise		-48,894	-53%	$4.09^*	43,773	12 Mar 2026	Common Stock	48,894	$4.09	Direct	F2
transaction	XERS	Stock Option (Right to Buy)	Options Exercise		-4	-0.01%	$3.94^*	79,996	12 Mar 2026	Common Stock	4	$3.94	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2	The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
F3	The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

Remarks:

President and Chief Operating Officer